Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20230331057788N1
IRCT20230331057788N1
Recruiting
Phase 4

CLINICAL EFFICACY OF DAPAGLIFLOZIN IN ASSOCIATION WITH GENETIC POLYMORPHISM AND ITS PLASMA LEVELS IN CHRONIC HEART FAILURE PATIENTS

ational University of Medical Sciences0 sites170 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic Heart Failure.Chronic combined systolic (congestive) and diastolic (congestive) heart failureI50.42

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Chronic Heart Failure.
Sponsor
ational University of Medical Sciences
Enrollment
170
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ational University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Pakistani patients of 18 years and above, males and females
  • •Diagnosed symptomatic heart failure (NYHA class 1–IV)
  • •Ejection fraction (EF) \= 40% on imaging study within last 12 months prior to enrolment
  • •Patient on stable GDMT of heart failure for \=4 weeks
  • •Both diabetic and non\-diabetic patients

Exclusion Criteria

  • •Type\-1 diabetics or patients having any history of DKA
  • •Patients having eGFR \= 25 ml/ min/ 1\.73 m2 as per (CKD\-EPI formula), systolic blood pressure (SBP) \< 95 mmHg
  • •Patients having MI, unstable angina, stroke, acute heart failure (HF) or any hospitalization due to acute HF \<4 weeks preceding enrolment
  • •Patients undergoing PCI /CABG or valvular replacement, any previous transplantation of heart or infixing of ventricular assistance device (VAD), implantation of Cardiac resynchronization therapy (CRT) within 3 months preceding enrolment or any plan to undergo after randomization
  • •Patients having active myocarditis, uncorrected primary valvular disease, restrictive or hypertrophic (obstructive) cardiomyopathy; bradycardia, 2nd or 3rd degree heart block without having any pacemaker
  • •Patients received any SGLT2i within 12 weeks preceding screening visit or hypersensitivity to Dapagliflozin
  • •Pregnant ladies and nursing mothers, severe COPD leading to dyspnea, any malignancy or hepatic impairment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
N/A
TO ASSESS EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH CIRRHOSIS WITH DIABETES AS COMPARED TO STANDARD MEDICAL REGIME
CTRI/2023/06/054459Pt BD Sharma Institute of Medical Science, Rohtak
Completed
N/A
A STUDY TO EVALUATE THE EFFECT OF DAPAGLIFLOZIN ON RENAL OUTCOMES AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE-N19 Unspecified kidney failureUnspecified kidney failureN19
PER-055-16ASTRAZENECA PERU S.A.,218
Not Yet Recruiting
N/A
Dapagliflozin in Heart Failure
CTRI/2022/11/047725Sanjay Kumar R
Not Yet Recruiting
N/A
A clinical trial to compare the efficacy of combination therapy of antidiabetic drugs dapagliflozin & metformin versus metformin alone in improving metabolic profile in overweight & obese women with polycystic ovary syndrome.Health Condition 1: E888- Other specified metabolic disordersHealth Condition 2: E66- Overweight and obesity
CTRI/2023/06/054098Dr Vishal Agarwal
Recruiting
N/A
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetes
JPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200